四个腺受体在肝纤维化中的不同作用
Lan Yang1, Zhao-Wei Gao1, Xi Wang1
1Department of clinical diagnose, Tangdu hospital, Air Force Medical University, Xi'an, Shaanxi, China.
Frontiers in pharmacology
|September 18, 2024
概括
氨酸受体A1R和A2AR通过促进肝星细胞活性来恶化肝纤维化,而A2BR和A3R激动剂显示出保护作用. 这突出了肝纤维化的独特治疗点.
科学领域:
- 免疫学 免疫学 免疫学
- 药理学 药理学是指药理学的学科.
- 肝病学 肝病学是一种肝病学.
背景情况:
- 腺-腺受体通路在免疫反应和炎症中至关重要.
- 四个腺受体 (A1R,A2AR,A2BR,A3R) 在疾病进展中具有不同的,有时是对立的作用.
- 了解这些作用对于开发向性肝纤维化疗法至关重要.
研究的目的:
- 为了研究激活腺受体A1R,A2AR,A2BR和A3R在肝纤维化背景下的特定作用.
- 确定这些受体如何影响肝星细胞 (HSC) 活性和肝纤维化模型中的增殖.
主要方法:
- 在C57BL/6小鼠中使用CCl4.4诱导肝纤维化.
- 特定的激动剂 (CCPA,CGS21680,BAY 60-6583,纳莫登) 被用于分别激活A1R,A2AR,A2BR和A3R.
- 评估了肝功能 (ALT,AST),组织学 (H&E,Masson,Sirius Red) 和HSC行为 (CCK8,划伤试验,α-SMA,Col1α1表达).
主要成果:
- A1R和A2AR激活加剧了肝纤维化,增加了肝损伤标志物和原沉积.
- A2BR和A3R激活缓解了肝纤维化,减少了损伤和原蛋白.
- A1R/A2AR激动剂增强了HSC的增殖和迁移,而A2BR/A3R激动剂则抑制了它们. 此外,NECA还显示出保护作用.
结论:
- 腺素受体A1R和A2AR通过促进HSC活动和增殖,起到亲纤维的作用.
- 腺素受体A2BR和A3R通过抑制HSCs表现出抗纤维性作用.
- 向特定的腺受体为治疗肝纤维化提供了潜在的治疗策略.
相关概念视频
Adrenergic Receptors: ɑ Subtype
1.5K
Adrenoceptors are classified into α and ꞵ classes based on their potencies to catecholamine agonists. α-adrenoceptors show the following order of catecholamine potency:
Adrenaline ≥ Noradrenaline >> Isoprenaline
α-adrenoceptors are further divided into α1 and α2-adrenoceptors.
α1-Adrenoceptors: These receptors are located postsynaptically on the effector organs and cause constriction of smooth muscle mediated by activation of phospholipase...
Adrenaline ≥ Noradrenaline >> Isoprenaline
α-adrenoceptors are further divided into α1 and α2-adrenoceptors.
α1-Adrenoceptors: These receptors are located postsynaptically on the effector organs and cause constriction of smooth muscle mediated by activation of phospholipase...
1.5K
Adrenergic Receptors: β Subtype
1.6K
β-adrenoceptors have varied sensitivities towards adrenaline, noradrenaline, and isoprenaline. The order of agonist potency is as follows:
Isoprenaline > Adrenaline > Noradrenaline
Neurotransmitter binding to these receptors causes activation of adenylyl cyclase resulting in increased concentrations of cAMP and modulation of calcium ion channels within the cell. They are further classified into β1, β2, and β3 subtypes.
β1-adrenoceptors: β1-adrenoceptors...
Isoprenaline > Adrenaline > Noradrenaline
Neurotransmitter binding to these receptors causes activation of adenylyl cyclase resulting in increased concentrations of cAMP and modulation of calcium ion channels within the cell. They are further classified into β1, β2, and β3 subtypes.
β1-adrenoceptors: β1-adrenoceptors...
1.6K
Adrenergic Receptors (Adrenoceptors): Classification
2.4K
Adrenergic receptors, or adrenoceptors, respond to the autonomic neurotransmitter noradrenaline and other endogenous catecholamine agonists. They are classified into two main families, α and β, based on their pharmacological response and are further subdivided depending on their location, elicited response, and affinity to specific agonists or antagonists.
α-Adrenoceptors
α-Adrenoceptors are classified into two main subtypes: α1 and α2. The α1 adrenoceptors,...
α-Adrenoceptors
α-Adrenoceptors are classified into two main subtypes: α1 and α2. The α1 adrenoceptors,...
2.4K
cAMP-dependent Protein Kinase Pathways
6.2K
Cyclic Adenosine Monophosphate (cAMP) is an essential second messenger that activates protein kinase A (PKA) and regulates various biological processes. A single epinephrine molecule binds to GPCR and activates several heterotrimeric G proteins, each stimulating multiple adenylyl cyclase, amplifying the signal, and synthesizing large numbers of cAMP molecules. Small changes in cAMP concentration affect PKA activity. The binding of four cAMP molecules induces a conformational change in PKA,...
6.2K
Adrenergic Antagonists: Pharmacological Actions of ɑ-Receptor Blockers
559
α-Adrenergic antagonists, known as α-blockers, exert their effects by inhibiting α-adrenoceptors, leading to specific physiological actions. α1-blockers and α2-blockers have distinct pharmacological actions and therapeutic applications.
α1-blockers: These drugs inhibit α1-adrenoceptors on smooth muscle cells, resulting in vasodilation. This vasodilation lowers blood pressure, making α1-blockers valuable in treating hypertension. Additionally,...
α1-blockers: These drugs inhibit α1-adrenoceptors on smooth muscle cells, resulting in vasodilation. This vasodilation lowers blood pressure, making α1-blockers valuable in treating hypertension. Additionally,...
559
Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers
791
Class IV antiarrhythmic drugs, such as verapamil and diltiazem, block calcium channels. They primarily affect the heart, slowing the conduction in calcium-dependent tissues like the SA and AV nodes. These drugs manage reentrant supraventricular tachycardia (SVT) and reduce ventricular rate in atrial flutter/fibrillation.
Verapamil, a calcium channel blocker, inhibits calcium movement across myocardial cell membranes and vascular smooth muscle. This results in the dilation of coronary and...
Verapamil, a calcium channel blocker, inhibits calcium movement across myocardial cell membranes and vascular smooth muscle. This results in the dilation of coronary and...
791


